Ligand to Report Second Quarter 2017 Results on August 7th
July 20 2017 - 4:01PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announced today plans to report second quarter 2017 financial
results on August 7, 2017. Ligand’s CEO John Higgins, President and
COO Matt Foehr and CFO Matt Korenberg will host the conference
call.
Second Quarter 2017 Earnings Call
What: Ligand conference call to discuss
financial results and provide general business updates When:
Monday, August 7, 2017 Time: 4:30 p.m. Eastern time (1:30
p.m. Pacific time) Conference Call: (833) 591-4752 within
the U.S. (720) 405-1612 outside the U.S. Conference ID - 59163454
Webcast:
Live conference call webcast and replay
accessible at www.ligand.com
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170720006133/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill(858)
550-7500investors@ligand.com@Ligand_LGNDorLHABruce Voss(310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024